Supriya Life Science – Dec 16 to 20

EspressoLogy

Supriya Life Science – Dec 16 to 20

December 14, 2021
Supriya Life Science – Dec 16 to 20

Supriya Lifescience Limited is coming out with a fresh public issue to raise Rs 700 crores from the market.

Key details of the issue:

  • Issue opens – Dec 16 (Thursday)
  • Issue closes – Dec 20 (Monday)
  • Issue size – Rs 700 crores
  • Price band – Rs 265 to 274 per equity share
  • Bid lot – 54 shares and in multiples thereof

And here are some details of the company and further details on the Supriya Lifescience Limited issue.

Company details:

Supriya Lifescience Limited (“SLL”) was incorporated on March 26, 2008. SLL is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (“APIs”), with a focus on research and development. Company’s focus is primarily on diverse therapeutic areas and niche products.

As of October 31, 2021, SLL has niche product offerings of 38 APIs focused on diverse therapeutic segments such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic. They have consistently been the largest exporter of Chlorpheniramine Maleate and Ketamine Hydrochloride from India. They were among the largest exporters of Salbutamol Sulphate contributing to 31% of the API exports from India in FY 2021 in volume terms.

Company’s products are registered with various international regulatory authorities such as USFDA, EDQM, NMPA (previously known as SFDA), KFDA, PMDA, TGA and Taiwan FDA. As of October 31, 2021, they have filed 14 active DMFs with USFDA and 8 active CEPs with EDQM, for their API products in therapeutic areas such as antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic and anti-allergic.

Company’s pharmaceutical business is organized into domestic and export sales. As of October 31 2021, their products were exported to 86 countries to 1,296 customers including 346 distributors.

 Company’s business operations are supported by a modern manufacturing facility located in Parshuram Lote, Maharashtra, spread across 23,806 sq.mt. They have 4 manufacturing blocks which are segregated therapeutic segment wise. The 4th block commenced operation in May 30, 2021.

Issue size: Rs 700 crores


Issue break-up:

  • QIB – 75% of the offer – Rs 525 crores
  • NIB – 15% of the offer – Rs 105 crores
  • RET – 10% of the offer – Rs 70 crores

Listing: NSE and BSE

Registrar: Link Intime India Private Limited

UPI: All retail applications through brokers are compulsorily in UPI mode

Not an Espresso customer, but still want to apply for the Supriya Lifescience IPO? Become an Espresso customer in just 15 mins* by tapping here and take it from there! (* T&C apply)

Team Espresso
by Team Espresso

We care that you succeed

Bringing readers the latest happenings from the world of Trading and Investments specifically and Finance in general.